FDA expansion of the Arexvy vaccine provides protection against RSV-related lower respiratory tract disease for at-risk adults aged 18 to 49 years. The Food and Drug Administration (FDA) has expanded ...
What Is Arexvy, and Why Does It Matter? Arexvy is a vaccine that helps protect against serious lung illness caused by respiratory syncytial virus (RSV). The FDA has expanded its use to include people ...
AREXVY was previously approved in the US for the prevention of RSV-related LRTD in adults aged 60 and older, and adults aged 50–59 at increased risk for LRTD caused by RSV. This vaccine is not for use ...
(RTTNews) - GSK plc (GSK, GSK.L) announced that its adjuvanted recombinant respiratory syncytial virus vaccine, Arexvy, has been approved by the European Commission for use in adults aged 18 years and ...
In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection1* GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has ...
GSK plc GSK announced that the FDA approved the expanded use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 18 to 49 years who are at a higher risk of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results